Mesa Laboratories MLAB Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharmaceutical Development | $48.63M-7.2% | $52.4M+4.2% | $50.26M+4.3% | $48.21M-1.1% | $48.73M+0.9% | |
| Clinical Genomics | $45.39M+1.5% | $44.72M-2.0% | $45.62M-0.8% | $45.97M-2.4% | $47.08M+0.8% | |
| Revenue by Product | ||||||
| Service | $45.74M+2.8% | $44.5M+1.9% | $43.69M+2.3% | $42.7M+0.3% | $42.58M+1.2% | |
| Revenue by Geography | ||||||
| CN | $20.45M-4.6% | $21.43M-3.1% | $22.11M-8.6% | $24.18M-4.5% | $25.31M-4.9% | |
| Other | $111.79M+3.4% | $108.07M+3.4% | $104.53M+3.7% | $100.77M+1.7% | $99.05M+0.5% | |
| US | $116.9M-1.0% | $118.04M-0.5% | $118.62M+1.0% | $117.4M+0.7% | $116.62M+3.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mesa Laboratories break its business down?
- Mesa Laboratories (MLAB) reports revenue by business across 3 parts — Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Each is extracted from the segment footnotes and tracked over time.
- Where does Mesa Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mesa Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
